141 related articles for article (PubMed ID: 23228190)
21. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H
Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
[TBL] [Abstract][Full Text] [Related]
23. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.
Okines AF; Ashley SE; Cunningham D; Oates J; Turner A; Webb J; Saffery C; Chua YJ; Chau I
J Clin Oncol; 2010 Sep; 28(25):3945-50. PubMed ID: 20679619
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
25. Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.
Yoo C; Ryu MH; Na YS; Ryoo BY; Lee CW; Maeng J; Kim SY; Koo DH; Park I; Kang YK
Invest New Drugs; 2014 Apr; 32(2):271-8. PubMed ID: 23712440
[TBL] [Abstract][Full Text] [Related]
26. Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy.
Jansen EPM; Boot H; Dubbelman R; Verheij M; Cats A
Ann Oncol; 2010 Mar; 21(3):530-534. PubMed ID: 19690058
[TBL] [Abstract][Full Text] [Related]
27. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
Eatock MM; Tebbutt NC; Bampton CL; Strickland AH; Valladares-Ayerbes M; Swieboda-Sadlej A; Van Cutsem E; Nanayakkara N; Sun YN; Zhong ZD; Bass MB; Adewoye AH; Bodoky G
Ann Oncol; 2013 Mar; 24(3):710-8. PubMed ID: 23108953
[TBL] [Abstract][Full Text] [Related]
28. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Rao S; Starling N; Cunningham D; Sumpter K; Gilligan D; Ruhstaller T; Valladares-Ayerbes M; Wilke H; Archer C; Kurek R; Beadman C; Oates J
Ann Oncol; 2010 Nov; 21(11):2213-2219. PubMed ID: 20497967
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
Salah-Eldin MA; Ebrahim MA; AL-Ashry MS
Anticancer Drugs; 2009 Mar; 20(3):191-6. PubMed ID: 19396018
[TBL] [Abstract][Full Text] [Related]
30. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.
Johnson FM; Krug LM; Tran HT; Shoaf S; Prieto VG; Tamboli P; Peeples B; Patel J; Glisson BS
Cancer; 2006 Jan; 106(2):366-74. PubMed ID: 16342249
[TBL] [Abstract][Full Text] [Related]
31. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.
Starling N; Hawkes EA; Chau I; Watkins D; Thomas J; Webb J; Brown G; Thomas K; Barbachano Y; Oates J; Cunningham D
Ann Oncol; 2012 Apr; 23(4):942-7. PubMed ID: 21750117
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas.
Trarbach T; Przyborek M; Schleucher N; Heeger S; Lüpfert C; Vanhoefer U
Invest New Drugs; 2013 Jun; 31(3):642-52. PubMed ID: 22763610
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancer.
Wu J; Ryan T; Levinson B; Newman E; Hochster HS; Muggia F
Anticancer Res; 2012 Mar; 32(3):939-45. PubMed ID: 22399614
[TBL] [Abstract][Full Text] [Related]
34. A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.
Bauman JE; Eaton KD; Wallace SG; Carr LL; Lee SJ; Jones DV; Arias-Pulido H; Cerilli LA; Martins RG
BMC Cancer; 2012 Oct; 12():449. PubMed ID: 23033932
[TBL] [Abstract][Full Text] [Related]
35. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Goel G; Jauhri M; Negi A; Aggarwal S
Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Tsai JY; Iannitti D; Berkenblit A; Akerman P; Nadeem A; Rathore R; Harrington D; Roye D; Miner T; Barnett JM; Maia C; Stuart K; Safran H
Am J Clin Oncol; 2005 Aug; 28(4):329-33. PubMed ID: 16062072
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
[TBL] [Abstract][Full Text] [Related]
38. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I
Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
[TBL] [Abstract][Full Text] [Related]
39. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
